DUBLIN, May 20, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Non-alcoholic Steatohepatitis Market 2016-2020" report to their offering.
The global NASH market is set to grow at a CAGR of 24.58% during the period 2016-2020.
NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis.
One noteworthy trend in the market is the availability of patient assistance programs. Patient assistance programs offered by vendors, designed to fit individual needs regarding liver diseases, help them attain access to medications. AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Novo Nordisk are among the companies that offer patient assistance programs, offering solutions such as co-pay assistance and coupons.
According to the report, a key driver of market growth is an increasingly sedentary lifestyle. An unhealthy or sedentary lifestyle and the intake of high calorie food results in the accumulation of excess body fat, causing problems such as obesity, diabetes, cardiovascular problems, and liver disease, which are the associated conditions for NASH. This provides drug manufacturers with opportunities to manufacture new and effective drugs, thereby boosting the growth of the global NASH drugs market.
Further, the report states that one challenge that could severely impact market growth is the limited understanding of the disease's pathophysiology.
- Arena Pharmaceuticals
- F Hoffmann-La Roche
- Novo Nordisk
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by dosage form
PART 09: Market segmentation by route of administration
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
For more information visit http://www.researchandmarkets.com/research/mnsws6/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-non-alcoholic-steatohepatitis-market-2016-2020----limited-understanding-of-disease-pathophysiology---research-and-markets-300272309.html
SOURCE Research and Markets